The MMAB gene encodes ATP:cob(I)alamin adenosyltransferase (ATR)¹¹ ATP:cob(I)alamin adenosyltransferase (ATR)
The enzyme that converts reduced cob(I)alamin to adenosylcobalamin (AdoCbl), the cofactor required by methylmalonyl-CoA mutase for propionate catabolism in mitochondria, a critical last step in the mitochondrial vitamin B12 processing pathway. When both copies of MMAB are non-functional, methylmalonyl-CoA cannot be converted to succinyl-CoA, and methylmalonic acid accumulates to toxic levels in blood, urine, and tissues — the condition known as methylmalonic aciduria cblB type²² methylmalonic aciduria cblB type
OMIM #251110; the 'cblB' designation refers to the complementation class originally defined by somatic cell fusion studies before the gene was identified. The variant at rs199971687 disrupts the splice acceptor site at the intron 3–exon 4 boundary of MMAB, destroying normal pre-mRNA processing and causing complete loss of functional ATR protein.

The Mechanism

The splice acceptor consensus sequence (AG at the 3′ end of each intron) is essential for the spliceosome to remove the intron and join exon 3 to exon 4. The c.291-1G>A and c.291-1G>T substitutions (both reported at rs199971687 on the coding/minus strand, appearing as C>T and C>A respectively on the plus strand in genome files) each destroy the invariant G of this AG dinucleotide. Functional studies on the G>A allele showed no normal mRNA transcripts at exon 4-containing sequences³³ no normal mRNA transcripts at exon 4-containing sequences
ClinVar VCV000219004, citing functional RNA analysis submitted by multiple clinical laboratories, confirming that the splice defect is complete rather than leaky.

The ATR enzyme functions as a homotrimer with three ATP-binding sites and two non-equivalent adenosylcobalamin-binding sites (Kd values of 0.55 µM and 8.4 µM). Forny et al. 2022⁴⁴ Forny et al. 2022
Forny P et al. Spectrum and characterization of bi-allelic variants in MMAB causing cblB-type methylmalonic aciduria. Hum Genet, 2022 showed that the propionate incorporation ratio — the ratio of propionate metabolism with and without added hydroxocobalamin — predicts both clinical cobalamin responsiveness and age of disease onset. Splice-site variants that eliminate mRNA entirely effectively produce a null allele; disease onset and responsiveness depends on what the second allele produces.

The Evidence

The two pathogenic alleles at this locus are both classified as Pathogenic in ClinVar: the G>A allele (ClinVar VCV000219004) carries criteria-provided review status with nine submitting laboratories including LabCorp, Invitae, Mayo Clinic, Baylor Genetics, and GeneDx. The G>T allele (ClinVar VCV001173991) was documented by the Baumgartner laboratory at the University Children's Hospital Zurich and reported in the Forny et al. 2022 case series.

Lerner-Ellis et al. 2006⁵⁵ Lerner-Ellis et al. 2006
Lerner-Ellis JP et al. Mutation and biochemical analysis of patients belonging to the cblB complementation class of vitamin B12-dependent methylmalonic aciduria. Mol Genet Metab, 2006 sequenced MMAB in 35 cblB patients and identified 19 mutations including four splice-site variants. The most common European pathogenic allele is p.(Arg186Trp) at c.556C>T, accounting for 29–33% of European cblB alleles; rs199971687 is a rare allele that has been observed primarily in individual case reports.

cblB-type MMA has a birth prevalence of approximately 1 in 159,614 in the US⁶⁶ 1 in 159,614 in the US
Manoli I et al., GeneReviews, Isolated Methylmalonic Acidemia, NCBI Bookshelf NBK1231, 2022, with higher rates in the Middle East, North Africa, and parts of East Asia due to founder effects and consanguinity. This makes obligate carriers — individuals with one loss-of-function MMAB allele — far more common than affected individuals, with an estimated carrier frequency of roughly 1 in 200 in European populations.

Practical Actions

For carriers (CT genotype): Carriers have one functional MMAB allele producing sufficient ATR enzyme to handle normal propionate metabolism. No metabolic symptoms occur in heterozygous carriers, and no dietary or supplementation changes are needed for the carrier's own health. The clinical significance of carrier status is entirely in the domain of family planning: if both parents carry a pathogenic MMAB allele, each pregnancy carries a 25% risk of producing an affected child.

For affected individuals (TT or homozygous/compound heterozygous for any two MMAB loss-of-function alleles): Treatment depends on cobalamin responsiveness. Approximately 40–50% of cblB patients show at least partial responsiveness to pharmacological-dose hydroxocobalamin⁷⁷ hydroxocobalamin
The natural, non-cyano form of B12; preferred over cyanocobalamin for cobalamin metabolism disorders because it is more efficiently retained and distributed to mitochondria. Standard assessment involves 1 mg hydroxocobalamin intramuscularly daily for 3–5 days; a reduction in urinary methylmalonic acid by >50% defines responsiveness. All cblB patients, regardless of responsiveness, require protein-restricted diet, emergency metabolic protocols during illness, and regular monitoring of methylmalonic acid, ammonia, renal function, and neurological status.

Interactions

MMAB loss-of-function sits at a node where several B12 processing pathways converge. AdoCbl is the exclusive cofactor for methylmalonyl-CoA mutase; without it, propionate catabolism halts regardless of circulating B12 levels. The downstream biochemical consequences — elevated propionylcarnitine, methylmalonic acid, and homocysteine — connect MMAB deficiency to the folate-methylation cycle. Carriers of common MTHFR variants (rs1801133) already have moderately elevated homocysteine; an MMAB carrier parent in a family with known cblB history should be aware of this compounding possibility in an affected child who has biallelic MMAB loss.

For genetic counseling purposes, rs199971687 should be interpreted in the context of the second MMAB allele. Many compound heterozygous cblB patients carry this splice-site allele on one chromosome and a missense allele (such as p.Arg186Trp) on the other. In those combinations, cobalamin responsiveness is determined by which allele retains more residual function — typically the missense allele.

Your immune system maintains a delicate balance between fighting threats and attacking your own body. At the center of this balance sits A20, a protein encoded by the TNFAIP3 gene¹¹ A20, a protein encoded by the TNFAIP3 gene
TNFAIP3 stands for TNF Alpha Induced Protein 3; A20 is its common protein name that functions as a master brake on inflammation. The F127C variant (rs2230926) weakens this brake, and the consequences ripple through your immune system — from joints to gut lining to salivary glands.

The Mechanism

A20 is a ubiquitin-editing enzyme²² ubiquitin-editing enzyme
Ubiquitin is a small protein tag that cells attach to other proteins to control their fate — marking them for destruction, altering their activity, or changing their interactions with a remarkable dual function. Its N-terminal OTU domain strips K63-linked ubiquitin chains³³ N-terminal OTU domain strips K63-linked ubiquitin chains
K63 ubiquitin chains activate inflammatory signaling proteins; removing them shuts the signal down from signaling proteins like RIP1, while its C-terminal zinc finger domain adds K48-linked chains⁴⁴ C-terminal zinc finger domain adds K48-linked chains
K48 ubiquitin chains tag proteins for destruction by the proteasome that target them for proteasomal degradation. This two-step process — deactivate then destroy — efficiently terminates NF-kB signaling after it has served its purpose.

When TNF-alpha or bacterial products trigger inflammation, NF-kB activates and rapidly induces A20 expression as a negative feedback loop⁵⁵ rapidly induces A20 expression as a negative feedback loop
A20's own promoter contains NF-kB binding sites, so inflammation triggers its own off-switch. The F127C variant sits in the OTU deubiquitinase domain, and the cysteine substitution reduces A20's ability to inhibit TNF-induced NF-kB activation⁶⁶ cysteine substitution reduces A20's ability to inhibit TNF-induced NF-kB activation
Functional studies show the Cys127 variant is less effective at suppressing NF-kB than the normal Phe127 form. The result: inflammatory signals persist longer and reach higher intensity than they should.

Beyond immune signaling, A20 plays a direct role in gut barrier integrity. TNFAIP3 maintains intestinal epithelial tight junctions⁷⁷ TNFAIP3 maintains intestinal epithelial tight junctions
A20 deubiquitinates occludin, a key tight junction protein, preventing its degradation and maintaining barrier function by regulating the ubiquitination of occludin. Mice lacking TNFAIP3 show increased intestinal permeability, while overexpression protects against barrier breakdown — directly linking A20 function to gut health.

The Evidence

The F127C variant has been associated with a striking breadth of autoimmune conditions. A genome-wide association study of 1,239 SLE cases⁸⁸ genome-wide association study of 1,239 SLE cases
Study included 1,629 controls of European ancestry found rs2230926 independently associated with systemic lupus erythematosus (OR 2.0, 95% CI 1.4-3.0). Meta-analysis of 18,501 SLE patients and 30,435 controls⁹⁹ Meta-analysis of 18,501 SLE patients and 30,435 controls
Analysis across 23 studies from 20 publications confirmed the association in both Europeans (OR 2.25, P<10^-9) and Asians (OR 1.9, P=8.6x10^-11). In the Japanese population specifically, the odds ratio was 1.92 (95% CI 1.53-2.41)¹⁰¹⁰ odds ratio was 1.92 (95% CI 1.53-2.41).

For rheumatoid arthritis, a meta-analysis of 21 case-control studies¹¹¹¹ meta-analysis of 21 case-control studies
Included stratification by ethnicity showing significant effects in Asian populations found rs2230926 increases risk with OR 1.39 (95% CI 1.11-1.72). A separate sequencing study across multiple autoimmune diseases¹²¹² sequencing study across multiple autoimmune diseases
Genotyped rs2230926 in 1,513 controls and patients with nine different autoimmune conditions demonstrated significant associations with Sjogren's syndrome (OR 3.38, P=0.038), Crohn's disease (OR 2.25, P=0.041), psoriasis (OR 2.17, P=0.037), and rheumatoid arthritis (OR 1.9, P=0.025).

The Sjogren's syndrome association is particularly notable. In a Greek cohort of 327 primary Sjogren's patients¹³¹³ In a Greek cohort of 327 primary Sjogren's patients
Compared against 448 healthy controls, the variant frequency was 8.0% versus 3.6% in controls (OR 2.3). Among patients who developed lymphoma before age 40, the frequency reached 18.2% (OR 6.0, 95% CI 1.8-19.8). Carriers showed elevated Bcl-XL expression — evidence of abnormal NF-kB activation providing a survival signal to B cells that can drive lymphoma.

The variant shows dramatic population stratification: the G allele frequency is approximately 3.3% in Europeans, 5.8% in East Asians, 3.1% in South Asians, and 36.7% in African populations. This high frequency in African populations suggests possible balancing selection, where the variant may confer advantages against certain infections despite increasing autoimmune risk.

Practical Implications

If you carry the G allele, your NF-kB inflammatory pathway has a weakened brake. This means your immune system is predisposed to sustained inflammatory responses that can target your own tissues. The practical value of knowing this genotype lies in targeted monitoring, NF-kB-modulating interventions, and awareness of which autoimmune symptoms to take seriously.

Curcumin (the active compound in turmeric) is one of the most studied natural NF-kB inhibitors. Clinical evidence supports its anti-inflammatory effects¹⁴¹⁴ Clinical evidence supports its anti-inflammatory effects
A capsule combining 150 mg curcumin, 75 mg resveratrol, and 150 mg EGCG reduced TNF-alpha-induced NF-kB activation in healthy volunteers at doses of 500-1,000 mg daily (as bioavailable formulations). Omega-3 fatty acids deserve special attention: the VITAL trial of 25,871 participants¹⁵¹⁵ VITAL trial of 25,871 participants
Randomized, double-blind, placebo-controlled trial over 5.3 years found that vitamin D supplementation reduced autoimmune disease incidence by 22% and omega-3s by 15%, with omega-3 benefits persisting two years after supplementation ended.

Vitamin D optimization is particularly relevant because vitamin D directly modulates NF-kB signaling and T-cell differentiation. For carriers of this variant, maintaining serum 25(OH)D above 40 ng/mL may provide additional immune-regulatory benefit beyond what standard recommendations offer.

Interactions

The TNFAIP3 F127C variant interacts with the broader autoimmune risk landscape. Carriers who also have PTPN22 R620W (rs2476601) face compounded autoimmune susceptibility, as both variants independently impair immune tolerance through different mechanisms — PTPN22 by lowering T-cell activation thresholds, and TNFAIP3 by prolonging NF-kB inflammatory signaling. The combination may be particularly relevant for rheumatoid arthritis and SLE risk.

TLR4 variants (rs4986790) may modulate the effects of impaired A20 function. Since A20 normally terminates NF-kB signaling downstream of TLR4, individuals with both altered TLR4 sensitivity and weakened A20 braking could have amplified or dampened inflammatory responses depending on which TLR4 variant they carry.

NOD2 variants (rs2066844, rs2066845) act in the same bacterial-sensing and NF-kB activation pathway in the gut. A20 normally dampens NF-kB signals triggered by NOD2 activation, so carriers of both NOD2 gain-of-function variants and TNFAIP3 loss-of-function variants may face compounded Crohn's disease risk through excessive intestinal NF-kB activity.

The IL2RA gene¹¹ IL2RA gene
IL2RA encodes CD25, the alpha chain of the high-affinity IL-2 receptor, essential for regulatory T cell (Treg) development and homeostasis harbors multiple independent regulatory variants that together determine how finely tuned your immune system's self-tolerance machinery is. rs2256774 is an intronic variant in IL2RA that operates in the same regulatory neighbourhood as the better-studied rs2104286²² rs2104286
rs2104286 is the index IL2RA MS/T1D risk variant affecting intron-1 methylation and soluble IL-2RA shedding, but contributes an independent signal. Fine-mapping studies of the IL2RA locus in multiple sclerosis have shown that rs2256774 and rs3118470 together provide the best genotype discrimination for MS risk³³ rs2256774 and rs3118470 together provide the best genotype discrimination for MS risk
Babron et al. demonstrated a combined relative risk of 3.54 between least- and most-at-risk genotype combinations at these two SNPs. The same locus has been identified in a genome-wide association study of psoriasis⁴⁴ genome-wide association study of psoriasis
GWAS Catalog GCST, beta=0.068, p=1×10⁻⁹ for psoriasis susceptibility at rs2256774, extending IL2RA's role across skin-directed and systemic autoimmune diseases.

The Mechanism

IL-2 signaling through the high-affinity receptor complex (CD25/CD122/CD132) is the master maintenance signal for Treg viability and function⁵⁵ master maintenance signal for Treg viability and function
IL-2R stimulation drives pSTAT5, which transcribes FoxP3 and anti-apoptotic genes essential for Treg identity and survival. Intronic variants in IL2RA alter the balance between membrane-anchored CD25 — which captures IL-2 for Treg activation — and soluble IL-2RA (sIL-2RA), a shed ectodomain fragment that acts as a decoy receptor⁶⁶ acts as a decoy receptor
sIL-2RA binds IL-2 with moderate affinity, sequestering it in serum and reducing availability for membrane-bound Treg receptors. When sIL-2RA is elevated, Tregs are present in normal numbers but receive insufficient IL-2 stimulation — a functionally hyporeactive state that impairs suppression of autoreactive T cells.

The IL2RA locus demonstrates allelic heterogeneity⁷⁷ allelic heterogeneity
Different variants at the same locus have distinct effects; one allele may preferentially associate with MS, another with T1D, and a third with both diseases. rs2256774 represents one node in this network: its T allele is associated with increased autoimmune susceptibility, while the C allele is protective. The mechanism parallels rs2104286⁸⁸ mechanism parallels rs2104286
rs2104286 alters allele-specific CpG methylation in intron-1, increasing IL2RA transcription and sIL-2RA shedding, though rs2256774 may act through a distinct regulatory element within the same gene.

The psoriasis connection is mechanistically coherent: psoriasis is a T-cell-driven inflammatory skin condition where Treg/Th17 imbalance⁹⁹ Treg/Th17 imbalance
In psoriatic plaques, reduced Treg suppressive capacity allows Th17 and Th1 effector cells to drive IL-17A and TNF-alpha production is a central driver of keratinocyte hyperproliferation. Impaired Treg function from IL2RA variants creates a permissive environment for psoriatic inflammation.

The Evidence

The most direct evidence for rs2256774's clinical relevance comes from two sources. In MS genetics, Babron et al.¹⁰¹⁰ Babron et al.
Babron MC et al. "Determination of the real effect of genes identified in GWAS: the example of IL2RA in multiple sclerosis." EJHG 2012 analysed 26 IL2RA variants in 522 MS trio families and 244 affected sib-pairs, finding that the two-SNP combination of rs2256774 and rs3118470 outperformed any single variant in discriminating case from control genotype distributions (p-corrected=0.009). The relative risk between least and most at-risk genotype combinations reached 3.54 (95% CI: 2.14–5.94) — a substantially larger effect than the modest single-SNP ORs typically observed at GWAS loci, suggesting that rs2256774 and rs3118470 together tag a haplotype with genuine functional consequence.

The 2007 NEJM MS GWAS¹¹¹¹ 2007 NEJM MS GWAS
International Multiple Sclerosis Genetics Consortium. "Risk alleles for multiple sclerosis identified by a genomewide study." NEJM 2007 identified IL2RA as a genome-wide significant MS risk locus (p=2.96×10⁻⁸) in 12,360 subjects, establishing the locus-level evidence that rs2256774 fine-mapping built upon. The psoriasis association (beta=0.068, p=1×10⁻⁹) represents an independent discovery across a different autoimmune phenotype, corroborating IL2RA's role in skin immune dysregulation.

Functional confirmation comes from Cerosaletti et al.¹²¹² Cerosaletti et al.
Cerosaletti K et al. "Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+CD25hi T cells." PLoS One 2013, who showed that IL2RA risk haplotype carriers demonstrate reduced pSTAT5 in CD4+CD25hi T cells despite normal or increased surface CD25, confirming the sIL-2RA shedding mechanism at the cellular level.

Practical Implications

Because rs2256774 modulates the same IL-2R axis as rs2104286, the actionable interventions overlap: strategies that strengthen Treg function through IL-2-independent pathways are particularly relevant for T-risk-allele carriers.

Vitamin D is a key intervention because 1,25-dihydroxyvitamin D3 drives Treg differentiation through VDR/TGF-beta1 signaling, providing a backup pathway when IL-2 access is limited. Omega-3 fatty acids (EPA in particular) reinforce Treg polarization through PPAR-gamma activation while DHA-derived specialized pro-resolving mediators suppress Th17 differentiation — directly countering the Treg/Th17 imbalance that drives psoriatic inflammation.

For psoriasis-specific monitoring, T-allele carriers should pay attention to skin changes suggestive of psoriasis onset — plaques on elbows, knees, scalp, or the lower back — and to triggers that precipitate flares in genetically susceptible individuals (streptococcal infections, certain medications, stress-induced immune dysregulation).

Interactions

rs2256774 operates within the broader IL2RA regulatory network. [Within the locus | Fine-mapping demonstrates at least three partially independent IL2RA signals in autoimmune disease], it acts in combination with rs3118470 and independently from rs2104286, together determining the magnitude of IL-2 signaling attenuation. Carriers of risk alleles at multiple IL2RA SNPs simultaneously may show additive impairment of Treg function.

Cross-locus interactions with CTLA4 rs3087243 are biologically plausible: CTLA4 delivers co-inhibitory signals that complement Treg suppression, and simultaneous impairment of both IL-2R signaling (rs2256774) and CTLA4 co-inhibition (rs3087243) could produce converging Treg dysfunction. These interactions belong in compound action analysis — individual recommendations here address each variant in isolation.

The follicle-stimulating hormone receptor (FSHR) is one of the most important genes in reproductive medicine. Encoded on chromosome 2q16.2 with the gene running on the minus strand, FSHR mediates the action of follicle-stimulating hormone (FSH) in both females — where it drives granulosa cell maturation, folliculogenesis, and ovarian response to exogenous gonadotropin stimulation — and in males, where it supports Sertoli cell function and spermatogenesis. Coding variants in FSHR, particularly rs6165 (Ala307Thr)¹¹ rs6165 (Ala307Thr)
Located in the extracellular hinge region; removes an O-linked glycosylation site and rs6166 (Asn680Ser)²² rs6166 (Asn680Ser)
Located in the intracellular domain; alters cAMP signaling kinetics after FSH binding, are among the most studied pharmacogenomic variants in IVF medicine.

rs2268363 lies in an intron of FSHR at GRCh38 position chr2:48,974,189, approximately 284 base pairs from the closely related intronic variant rs2268361. Its position within the gene means it does not directly alter the FSH receptor protein. Instead, as an intronic tag variant, it may capture information about the underlying haplotype architecture of the FSHR locus — the combination of nearby variants that a given chromosome carries. The G allele occurs at 16% globally, with pronounced ancestry variation: approximately 14% in Europeans, 25% in East Asians, and 42% in African populations.

The Mechanism

As an intronic variant with a CADD score of approximately 11, rs2268363 has no predicted direct functional consequence on the FSH receptor protein. Its biological significance, to the extent it exists, derives from linkage disequilibrium with nearby functional variants across the FSHR locus. The FSHR gene harbors multiple well-characterized regulatory and coding variants — including the promoter SNP rs1394205 (G-29A), which reduces FSHR transcription, and the coding pair rs6165/rs6166 that form the Ala307Thr-Asn680Ser haplotype associated with reduced FSH receptor sensitivity. An intronic variant in close proximity to rs2268361 may partially tag one or more of these haplotypes, particularly in populations where relevant LD patterns are maintained.

The Evidence

The only published genome-wide significant association for rs2268363 is its identification in a 2010 GWAS by Kerns et al.³³ a 2010 GWAS by Kerns et al.
Genome-wide association study to identify SNPs associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 2010 as associated with [erectile dysfunction | Inability to achieve or maintain an erection, here specifically as a late adverse effect of pelvic radiation therapy] after radiotherapy for prostate cancer in African-American men (79 patients total; unadjusted p=5.46×10⁻⁸, Bonferroni p=0.028). The investigators proposed that FSHR expression in penile vascular and neural structures might modify radiation sensitivity in these tissues.

This finding was not validated in a subsequent attempt: Schack et al. 2017⁴⁴ Schack et al. 2017
Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. Acta Oncol, 2017 tested rs2268363 among nine radiotherapy-morbidity SNPs in a Danish prostate cancer cohort and could not replicate the original GWAS signal. This is not unusual for GWAS findings from small discovery cohorts — the Kerns 2010 study included only 79 African-American patients, and genomic signals from underpowered studies frequently fail replication.

No direct evidence links rs2268363 specifically to IVF outcomes or ovarian stimulation response. The fertility pharmacogenomics literature on FSHR focuses primarily on rs6165, rs6166, rs1394205, and rs2268361 — all of which are distinct variants. Attributing ART relevance to rs2268363 would require either direct evidence (which is absent) or demonstration of strong linkage disequilibrium with a variant that does have such evidence, which has not been published.

The nearby rs2268361 (284 bp upstream) has been studied in PCOS susceptibility cohorts⁵⁵ cohorts
Saxena et al. 2015, Human Reproduction: rs2268361-T associated with lower FSH levels in European women, P=0.0029 and reproductive phenotypes, but it is a distinct variant and its LD relationship with rs2268363 has not been reported in the published literature.

Practical Implications

For males: the G allele at rs2268363 was associated with a higher risk of erectile dysfunction following pelvic radiotherapy for prostate cancer in one African-American cohort — an association that was not subsequently validated. Men of African ancestry undergoing pelvic radiation therapy may wish to note this result in discussions with radiation oncologists about post-treatment sexual health monitoring, though the evidence does not yet support clinical use of this genotype for decision-making.

For females: there is no published evidence that rs2268363 specifically affects ovarian stimulation response, IVF outcomes, or FSH receptor function in the context of ART. Women who are concerned about their FSH receptor pharmacogenomics profile should prioritize results from rs6165, rs6166, and rs1394205 — the coding and promoter variants with substantial clinical evidence.

The FSHR locus is important for reproductive pharmacogenomics, and rs2268363 is a marker within that locus. As sequencing studies become larger and more ethnically diverse — particularly including African ancestry populations where the G allele is most common — the haplotype contribution of rs2268363 to FSH receptor function may be clarified.

Interactions

rs2268361 (FSHR intronic): The nearest characterized neighbor in FSHR, 284 bp downstream. rs2268361-T is associated with lower basal FSH levels in European women and has been studied in PCOS cohorts across multiple ancestries. The LD relationship between rs2268361 and rs2268363 in different populations has not been characterized in published studies but is likely relevant given their physical proximity.

rs6165 and rs6166 (FSHR coding variants): The primary pharmacogenomic variants at this locus with well-documented effects on ovarian stimulation response in IVF. These coding variants, which form the Ala307Thr-Asn680Ser haplotype, are the actionable variants for ART planning. Their LD relationship with rs2268363 across the full FSHR haplotype block has not been directly reported but is a relevant question for future multi-variant FSHR studies.

rs1394205 (FSHR promoter G-29A): The promoter variant that reduces FSHR transcription; independently studied in additive diplotype analyses alongside rs6165/rs6166. Like rs2268363, it is non-coding, but its mechanistic role (regulating receptor expression level) is established in functional studies.

The TMPRSS6 gene encodes matriptase-2¹¹ matriptase-2
A type II transmembrane serine protease expressed primarily in the liver, whose primary role is to cleave hemojuvelin and thereby suppress hepcidin production, the master regulator of hepcidin²² hepcidin
A 25-amino-acid peptide hormone produced by the liver that controls systemic iron homeostasis by degrading ferroportin, the sole iron export channel on gut enterocytes and macrophages. When matriptase-2 functions normally, it suppresses hepcidin, allowing dietary iron to cross from the gut into the bloodstream. When matriptase-2 activity is reduced — whether from coding variants like rs855791 or regulatory variants that modulate gene expression — hepcidin rises and iron absorption falls.

The rs228918 variant sits approximately 2 kilobases upstream of the TMPRSS6 transcription start site, within the gene's 5' regulatory region. Unlike the well-characterized coding variant rs855791 (Ala736Val), rs228918 does not change the matriptase-2 protein itself. Instead, it lies in a region that influences how much matriptase-2 the liver produces. Variants in this region have been examined across multiple ethnic cohorts as part of the broader TMPRSS6 locus.

The Mechanism

As a regulatory variant, rs228918 is thought to influence TMPRSS6 expression levels rather than enzymatic function directly. The upstream region of TMPRSS6 contains binding sites for transcription factors involved in liver iron sensing, including elements responsive to the BMP/SMAD signaling pathway³³ BMP/SMAD signaling pathway
Bone morphogenetic protein / son of mothers against decapentaplegic: a liver-expressed signaling cascade that drives hepcidin gene transcription in response to iron loading. A variant that reduces TMPRSS6 transcription would produce less matriptase-2, leave more hemojuvelin intact on liver cell surfaces, and consequently drive higher hepcidin production — the same downstream consequence as a loss-of-function coding variant, achieved through reduced gene expression.

The C allele (minor allele at rs228918) is associated with the iron-reducing direction. This is consistent with the broader TMPRSS6 locus pattern in GWAS: several upstream and intronic variants near rs228918 (including rs228921, rs228919, and the coding rs4820268) travel together as a haplotype, and the minor allele consistently tags lower iron stores compared to the reference allele.

The Evidence

A systematic review with meta-analyses⁴⁴ systematic review with meta-analyses
Gichohi-Wainaina WN et al. Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators. Genes Nutr, 2015 examined eight TMPRSS6 SNPs — including rs228918 — across 11 Caucasian, 4 Asian, and 1 African-American study cohort. The analysis documented inter-ethnic differences in minor allele frequencies, with rs228918 showing consistent directionality across populations. Effect sizes for this regulatory variant were smaller and less precisely estimated than for rs855791, reflecting its role as a locus-depth signal rather than the primary functional driver.

In a cohort of 686 South African women⁵⁵ cohort of 686 South African women
Gichohi-Wainaina WN et al. Common variants and haplotypes in the TF, TNF-alpha, and TMPRSS6 genes are associated with iron status in a female Black South African population. J Nutr, 2015, the haplotype carrying the protective (T) allele at rs228918 combined with the protective allele at rs228921 was associated with lower odds for elevated soluble transferrin receptor concentrations above 8.3 mg/L (OR 0.79; 95% CI 0.63, 0.98). Elevated soluble transferrin receptor is a sensitive marker of iron deficiency at the tissue level, rising before hemoglobin falls.

A 2016 multi-cohort study⁶⁶ 2016 multi-cohort study
Gichohi-Wainaina WN et al. Associations between common variants in iron-related genes with haematological traits in populations of African ancestry. PLoS One, 2016 in 2,073 individuals across four African ancestry cohorts (Kenya, Tanzania, South Africa, African Americans) confirmed that TMPRSS6 variants contribute to hemoglobin variation even in populations where the primary coding variant rs855791 has lower frequency.

Practical Implications

The practical consequences of rs228918 are directionally identical to those of rs855791 but likely smaller in magnitude. The C allele tags a modest reduction in iron absorption efficiency, mediated through lower TMPRSS6 expression and consequently higher hepcidin. For most people carrying one or two C alleles and eating a balanced diet with adequate iron, this has no clinical consequence.

The effect becomes relevant when iron demand increases: during menstruation, pregnancy, adolescent growth, vegetarian or vegan dietary patterns, or endurance athletics. In these situations, even modest reductions in iron absorption efficiency can contribute to suboptimal iron stores over time. Prioritizing bioavailable iron sources, pairing plant iron with vitamin C, and periodic ferritin monitoring are proportionate responses.

If you also carry the more potent coding variant rs855791 AA genotype, the regulatory effects of rs228918 add to the functional deficit. The combination of reduced TMPRSS6 expression (this variant) and reduced matriptase-2 enzymatic activity (rs855791) compounds the hepcidin-raising effect.

Interactions

rs228918 and rs855791 are both in the TMPRSS6 locus on chromosome 22. They are partially correlated through linkage disequilibrium but are not identical signals — rs228918 captures variation in TMPRSS6 expression while rs855791 captures variation in matriptase-2 enzyme activity. The combined effect of carrying the C allele at rs228918 and the A allele at rs855791 is likely additive within the hepcidin pathway.

rs228918 also has documented haplotype structure with rs228921 (located approximately 196 bp downstream at chr22:37,110,836), and these two upstream variants often travel together. The protective allele combination (T at both loci on the plus strand) is associated with better iron status than the risk haplotype (C at both loci) in population studies.

For people who also carry HFE variants (rs1800562 C282Y or rs1799945 H63D), the directionality matters: TMPRSS6 variants raise hepcidin (reducing absorption) while HFE variants lower it (increasing absorption). These opposing effects require blood-test confirmation of actual iron status rather than relying on genetics alone.

Every time your body encounters a pathogen — a bacterium, virus, or fungus — a molecular alarm system fires inside your immune cells. At the heart of this alarm is NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells)¹¹ NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells)
A family of transcription factors that control the expression of hundreds of immune and inflammatory genes, and NFKB1 encodes its critical p105/p50 subunit. Without adequate NF-κB1 activity, innate and adaptive immunity both falter. The rs230523 variant is a common intronic polymorphism in NFKB1 that was identified in a large-scale genome-wide association study as a modest but highly significant contributor to infection susceptibility.

The Mechanism

NFKB1 encodes two related proteins: the full-length p105 precursor, which acts as an inhibitor of NF-κB in the cytoplasm, and the processed p50 subunit, which dimerizes with p65 (RelA) to form the canonical NF-κB transcriptional activator. When pattern recognition receptors such as Toll-like receptors detect pathogen components, signaling cascades degrade the inhibitor IκB, freeing p50-p65 dimers to translocate into the nucleus and switch on hundreds of target genes — including cytokines (IL-6, TNF-α, IL-1β), chemokines, adhesion molecules, and antimicrobial peptides. rs230523 lies within an intron and does not alter the protein sequence, but intronic variants can influence splicing efficiency, mRNA stability, or regulatory element activity²² splicing efficiency, mRNA stability, or regulatory element activity
Many intronic variants alter binding sites for splicing regulators or transcription factors without changing the coded amino acids. The precise regulatory mechanism for rs230523 has not been characterized at the molecular level.

The clinical importance of the NFKB1 gene itself is well-established. Rare loss-of-function mutations in NFKB1 cause haploinsufficiency³³ loss-of-function mutations in NFKB1 cause haploinsufficiency
Having only one functional copy of the gene, producing approximately half the normal amount of p50 protein and are the most frequent single-gene cause of Common Variable Immunodeficiency (CVID)⁴⁴ Common Variable Immunodeficiency (CVID)
The most prevalent symptomatic antibody deficiency, characterized by recurrent bacterial infections and hypogammaglobulinemia, accounting for 4–5% of CVID cases in European cohorts. The rs230523 GWAS signal likely reflects a common, milder perturbation of NFKB1 regulation that sits on a continuum with these rarer, more severe loss-of-function variants.

The Evidence

Tian et al. (2017)⁵⁵ Tian et al. (2017)
Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. Nature Communications. conducted 23 genome-wide association studies for common infections in over 200,000 individuals of European ancestry through 23andMe. rs230523, mapping to NFKB1 on chromosome 4, reached genome-wide significance for overall infection susceptibility (OR≈1.07, P=4.5×10⁻¹⁴). While the per-allele odds ratio of 1.07 is modest, the extreme statistical significance across a very large, well-powered sample confirms this is a genuine genetic association rather than a false positive. The study captured self-reported lifetime history of common infections across 23 conditions including respiratory infections, urinary tract infections, and viral illnesses.

Chong et al. (2024)⁶⁶ Chong et al. (2024)
A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy. American Journal of Human Genetics. used serology-based GWAS in 9,611 UK Biobank participants — measuring actual antibody titers against 45 pathogen antigens — with validation in 487,297 participants. The NFKB1 locus emerged as the top signal influencing antibody responses to herpes, retro-, and polyomaviruses. The functional causal variant at this locus was proposed to be rs28362491, a 4-base-pair insertion- deletion in the NFKB1 5' regulatory region that affects gene expression; rs230523 likely tags the same functional signal through linkage disequilibrium.

On the rarer-variant side, Fliegauf et al. (2015)⁷⁷ Fliegauf et al. (2015) demonstrated that haploinsufficiency causing ~50% reduction in p50 protein leads to CVID with recurrent bacterial infections, while Li et al. (2021)⁸⁸ Li et al. (2021) systematically showed that among 90 variants found in CVID patients, 59 were biochemically deleterious, compared to only 2 of 260 population variants — establishing a strong genotype-phenotype relationship across the NFKB1 allelic spectrum.

Practical Actions

The OR of 1.07 per C allele translates to a small absolute risk increment — roughly 7% more likely to report having had a common infection, not 7 percentage points more likely overall. For CC homozygotes (two risk alleles), this compounds to approximately 14% increased relative likelihood. The practical implication is a modest tilt in innate immune responsiveness, most relevant when the immune system is already stressed: during novel pathogen exposure, periods of intense physical stress, or with suboptimal micronutrient status.

NF-κB1 activity depends on adequate zinc, vitamin D, and selenium — micronutrients that act as co-regulators of NF-κB pathway components. Ensuring optimal levels of these supports the immune gene expression network that NF-κB1 coordinates.

Interactions

The most important functional variant at this locus is likely rs28362491 (the -94ins/delATTG variant in the NFKB1 5' UTR), which has been independently associated with infection susceptibility and altered NFKB1 expression. rs230523 and rs28362491 are in the same chromosomal region and may tag the same causal signal; if both are measured, their combined interpretation should be treated with caution to avoid double-counting the same underlying effect.

TLR signaling variants (such as rs4986790 in TLR4 and rs5743708 in TLR1) act upstream of NF-κB activation. When both a TLR signaling variant and an NFKB1 variant are present, the downstream NF-κB response to pathogen recognition may be doubly attenuated, compounding infection susceptibility through both receptor-level and transcription-factor-level mechanisms.

The lymphotoxin-beta receptor (LTBR, also known as TNFRSF3) is a cell-surface receptor of the tumor necrosis factor receptor superfamily¹¹ tumor necrosis factor receptor superfamily
TNFRSF members are structurally related receptors that bind TNF-family cytokines and regulate inflammation, cell survival, and lymphoid organ development that governs how your immune cells build and maintain organized lymphoid architecture. LTBR sits at the hub of a signaling network that tells stromal cells to differentiate into the specialized vasculature and reticular scaffolds that make lymph nodes, Peyer's patches, and other secondary lymphoid organs function. Without proper LTBR signaling, these structures fail to form — and without well-organized lymphoid tissue, the immune system cannot mount ordered, antigen-specific responses.

rs2364480 is a synonymous coding variant in LTBR on chromosome 12p13.31: the nucleotide change (C→A at position 6386109, GRCh38) does not alter the alanine at protein position 172, but synonymous variants are not necessarily silent. They can affect codon usage and translation kinetics²² codon usage and translation kinetics
Different codons for the same amino acid are translated at different speeds; slower translation at critical points can alter how the protein folds co-translationally, mRNA stability, and splicing efficiency — mechanisms that have been documented for synonymous SNPs in other immune-receptor genes.

The Mechanism

LTBR receives signals from two main ligands: the lymphotoxin-αβ heterodimer (LTα1β2) secreted by activated T and B cells, and LIGHT (TNFSF14) expressed on activated T cells and NK cells. Upon ligation, LTBR activates two parallel NF-κB pathways³³ NF-κB pathways
NF-κB is a master transcription factor controlling inflammation, immune development, and cell survival — LTBR uniquely activates both the canonical (RelA/p50) and the non-canonical (RelB/p52) arms. The canonical arm drives acute inflammatory gene expression (IL-8, chemokines). The non-canonical arm, requiring NIK and IKKα, controls expression of chemokines (CXCL13, CCL19, CCL21) that recruit and position lymphocytes for optimal antigen encounters. This non-canonical pathway is also responsible for LTBR's critical role in lymph node organogenesis and tertiary lymphoid structure formation.

In rheumatoid arthritis, LTBR is overexpressed in synovial tissue⁴⁴ LTBR is overexpressed in synovial tissue
In one study correlating synovial cytokine expression with clinical measures, LTBR mRNA positively correlated with TNF-α, IFN-γ, and IL-15 levels, suggesting a feedback amplification loop in inflamed joints, where excess LTBR signaling drives formation of ectopic lymphoid tissue (ELT) — structures resembling lymph nodes that sustain local autoimmune responses. In IgA nephropathy, LTBR protein is detected in renal tubular epithelial cells and glomeruli⁵⁵ LTBR protein is detected in renal tubular epithelial cells and glomeruli
Induction of LTβ mRNA was identified in microarrays from both IgAN and lupus nephritis patients, and LTβR-Ig treatment attenuated nephritis severity in animal models, where it drives local NF-κB activation and renal inflammatory cascades.

The Evidence

The strongest genetic evidence for the LTBR locus in autoimmunity comes from a landmark GWAS of ankylosing spondylitis⁶⁶ GWAS of ankylosing spondylitis
The Australo-Anglo-American Spondyloarthritis Consortium (TASC) and Wellcome Trust Case Control Consortium 2 (WTCCC2) combined ~10,000 AS patients and controls in the largest AS genetic study at the time: the LTBR-TNFRSF1A region on chromosome 12p13 was associated with AS at genome-wide significance (rs11616188, combined P=4.1×10⁻¹²). This implicates the LTBR locus — not a single variant, but a chromosomal neighborhood of immune-signaling genes — in the genetic architecture of spondyloarthropathy.

For rs2364480 specifically, a Korean pediatric study⁷⁷ Korean pediatric study
199 children with biopsy-confirmed IgA nephropathy and 289 age-matched controls, genotyped by direct sequencing found the C allele of rs2364480 nominally associated with IgAN risk (p=0.041). The haplotype analysis was stronger: the TAA haplotype spanning rs3759333, rs3759334, and rs2364480 was significantly associated with IgAN (p=0.008 codominant). These findings are modest in isolation — a single study in one population with borderline p-values — but they are biologically coherent with the known role of LTBR in renal inflammation and the GWAS evidence at the broader locus.

Therapeutically, baminercept⁸⁸ baminercept
A fusion protein of the LTβR extracellular domain with human IgG1 Fc; it acts as a decoy receptor, capturing lymphotoxin and LIGHT before they reach cell-surface LTBR — an LTβR-Ig fusion protein — was tested in a Phase II RCT for primary Sjögren's syndrome (52 patients, 24 weeks). While baminercept mechanistically reduced CXCL13 and altered B/T cell trafficking consistent with LTβR blockade, it did not significantly improve glandular endpoints. This underscores the complexity of LTBR signaling in established autoimmune disease, but also validates that LTBR is a genuine pharmacological target in this pathway.

Practical Implications

Carriers of the CC genotype (the minor/risk genotype at ~4% frequency globally) carry two copies of the less-common C allele, which in the haplotype context associates with modestly altered LTBR signaling and nominal IgAN susceptibility in the published literature. For heterozygous AC carriers (~31%), the evidence for any clinically meaningful impact is limited; the current data support a monitoring posture rather than active intervention. For the common AA genotype (~65%), the population default — normal LTBR signaling and no signal for elevated autoimmune risk from this specific variant.

Interactions

rs2364480 sits within a haplotype block studied alongside the LTBR promoter variants rs3759333 (-1387C/T) and rs3759334 (-1326A/G). The TAA haplotype (rs3759333-T / rs3759334-A / rs2364480-A, using the Korean study's minor-allele notation) showed the strongest IgAN association (p=0.008), suggesting these three variants act together to modulate LTBR promoter activity and coding-region translational efficiency. The existing LTBR catalog entry rs10849448 (a 5'UTR regulatory variant with strong evidence for infection susceptibility) represents a distinct functional signal at the same gene — the two variants are not in tight LD and likely affect different aspects of LTBR biology.

The LTBR-TNFRSF1A chromosomal neighborhood (12p13) is a genetic hub for TNF-superfamily signaling. Carriers of risk alleles at TNFRSF1A (rs4149584, encoding R92Q in TNF receptor 1) combined with rs2364480 CC may face a compounded deficit in TNF-family receptor regulation — a proposed compound action candidate warranting future investigation.

Aromatase¹¹ Aromatase
the enzyme encoded by CYP19A1 that catalyzes the final and rate-limiting step of estrogen biosynthesis, converting androgens such as androstenedione and testosterone to estrogens is expressed in the ovaries, adipose tissue, bone, brain, and adrenal glands. Because it is the only enzyme capable of estrogen synthesis in vertebrates, even small changes in its expression can meaningfully shift the androgen–estrogen balance. The rs2414096 variant lies in intron 4 of CYP19A1 on chromosome 15 and does not alter the protein sequence, but several lines of evidence suggest it may influence aromatase expression levels or transcript regulation, with downstream effects on androgen-to-estrogen conversion.

The Mechanism

As an intronic variant, rs2414096 does not directly alter aromatase enzyme structure. Instead, it may act through effects on splicing efficiency, mRNA stability, or linkage disequilibrium with nearby regulatory elements. CYP19A1 is a complex locus with multiple tissue-specific promoters controlling aromatase expression in different organs; intronic variants can modulate these promoter activities in tissue-specific ways. The variant is located on chromosome 15 at position 51,237,582 (GRCh38), within intron 4, and CYP19A1 itself is transcribed from the minus strand²² CYP19A1 itself is transcribed from the minus strand. The GRCh38 reference allele (G) — corresponding to a C on the coding strand — appears to be the allele associated with lower aromatase activity based on multiple functional and association studies.

The Evidence

The primary evidence base consists of association studies across multiple populations, two meta-analyses, and a study linking this variant to direct hormone-level differences.

A 2021 meta-analysis of seven studies (1,414 PCOS cases, 1,276 controls) by Sharma et al.³³ A 2021 meta-analysis of seven studies (1,414 PCOS cases, 1,276 controls) by Sharma et al.
CYP19 gene rs2414096 variant and differential genetic risk of polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol 2021 found that the GG dominant model (GG+GA vs AA) was significantly associated with PCOS risk (OR=1.60, 95% CI 1.10–2.31, p=0.01), with the overall A-allele effect estimate of OR=0.74 (95% CI 0.62–0.88, p=0.0008), indicating the A allele is protective. The association was statistically significant in non-Indian populations but not Indian subpopulations, where genetic diversity is greater.

However, a larger 2022 meta-analysis by Xing et al. of 26 studies (4,860 PCOS cases, 4,043 controls)⁴⁴ a larger 2022 meta-analysis by Xing et al. of 26 studies (4,860 PCOS cases, 4,043 controls)
The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility. Front Physiol 2022 found no statistically significant overall association (OR=0.87, p=0.578) with extreme heterogeneity (I²=95.9%), underscoring that this variant's effects are genuinely population-dependent rather than universal.

Genotype-specific hormone data strengthen the mechanistic case. An analysis of 394 Kashmiri PCOS patients and 306 controls found that the GG genotype was associated with significantly elevated DHEAS, androstenedione, testosterone, and free androgen index⁵⁵ An analysis of 394 Kashmiri PCOS patients and 306 controls found that the GG genotype was associated with significantly elevated DHEAS, androstenedione, testosterone, and free androgen index
Ashraf et al. 2021. Impact of rs2414096 polymorphism of CYP19 gene on susceptibility of polycystic ovary syndrome and hyperandrogenism in Kashmiri women. Sci Rep 2021 (all comparisons p<0.05), supporting the hypothesis that the G allele reduces aromatase-driven androgen conversion. Similarly, a South Indian study of 150 PCOS patients found GG more prevalent among cases, with elevated LH/FSH ratios in GG carriers, and concluded that GG may exhibit reduced aromatase activity with subsequent hyperandrogenism⁶⁶ South Indian study of 150 PCOS patients found GG more prevalent among cases, with elevated LH/FSH ratios in GG carriers, and concluded that GG may exhibit reduced aromatase activity with subsequent hyperandrogenism
Hegde et al. 2023. Delineating the role of single-nucleotide polymorphism of CYP19 gene on aromatase activity in South Indian women with PCOS. J Genet Eng Biotechnol 2023.

On the question of circulating hormones, the SWAN study of 1,538 multiethnic midlife women found that Caucasian women with the AA genotype had markedly lower SHBG levels after adjusting for age and BMI⁷⁷ the SWAN study of 1,538 multiethnic midlife women found that Caucasian women with the AA genotype had markedly lower SHBG levels after adjusting for age and BMI
Sowers et al. 2006. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am J Med 2006. Lower SHBG increases free testosterone bioavailability, which may appear directionally contradictory to the PCOS data above — it suggests AA carriers have higher free androgen exposure despite a proposed protective effect on PCOS. This likely reflects tissue-specific or context-specific aromatase regulation: ovarian aromatase activity and circulating SHBG regulation are influenced by different promoters and feedback mechanisms. Context matters, and a single intronic variant almost certainly does not have a unidirectional effect across all tissues simultaneously.

Practical Actions

For women with PCOS features — irregular cycles, hirsutism, elevated androgens, or anovulatory infertility — the GG genotype adds a modest piece of evidence supporting impaired androgen-to-estrogen conversion in the ovary. This reinforces evaluation of androgen levels alongside this genotype, and consideration of aromatase-relevant interventions when clinically appropriate. Letrozole (an aromatase inhibitor paradoxically used to stimulate ovulation in PCOS by briefly lowering estrogen feedback, prompting FSH surge) is the standard-of-care first-line ovulation induction agent in PCOS; whether this genotype modifies letrozole response is an open question with no prospective pharmacogenomic data yet.

The heterogeneous evidence means this variant should be interpreted in the context of clinical findings, not used as a standalone diagnostic marker.

Interactions

Rs2414096 is part of the CYP19A1 locus alongside rs700518 (Val80, synonymous variant affecting aromatase expression and AI side-effect risk), rs700519 (Arg264Cys, coding variant with increased catalytic activity in vitro), and rs1062033 (intronic regulatory variant with CEBPβ-mediated transcriptional effect on aromatase in bone). These variants form haplotypes and may have compounded effects on total aromatase expression and activity — their combined influence on androgen–estrogen balance in reproductive tissues, bone, and adipose tissue is likely greater than any individual variant's effect alone. Women carrying risk genotypes across multiple CYP19A1 loci may have a broader pattern of altered estrogen synthesis worth evaluating with comprehensive hormone panels.

The chromosome 5q35.2 region was one of four genome-wide significant loci first identified in the landmark 2009 GWAS of 17,438 women¹¹ GWAS of 17,438 women
He et al. 2009, Nature Genetics — the first genome-wide scan for menopause-timing variants. At the center of this locus sits UIMC1 (also called RAP80) — a BRCA1 adaptor protein — and nearby, approximately 71 kb downstream, ZNF346 (zinc finger protein 346, also known as JAZ). The intronic variant rs244715 in ZNF346 is a proxy SNP for this locus, in partial linkage disequilibrium with the index UIMC1 coding variant rs365132 (r²=0.677 in European populations). Each G allele at rs244715 may be associated with a modest shift toward earlier menopause onset.

The Mechanism

The 5q35.2 locus is anchored biologically by UIMC1 (ubiquitin interaction motif containing 1), a protein that physically interacts with BRCA1 and is required to recruit the BRCA1-A complex to sites of DNA double-strand breaks. This recruitment initiates G2/M checkpoint control²² G2/M checkpoint control
The G2/M checkpoint prevents cells with damaged DNA from dividing; failure of this checkpoint accelerates DNA damage accumulation in dividing cells and homologous recombination repair. Because oocytes are some of the most DNA-damage-sensitive cells in the body — they can arrest in meiosis for decades and are exposed to oxidative stress throughout a woman's reproductive life — efficient DNA repair is critical for maintaining follicular integrity. Impaired repair capacity at this locus may accelerate the rate at which follicles accumulate irreparable DNA damage, triggering apoptosis and depleting the ovarian reserve prematurely.

ZNF346 itself adds a plausible second layer. As a nucleolar zinc finger protein (also called JAZ — "just another zinc finger protein"), it preferentially binds double-stranded RNA rather than DNA, and has been shown to positively regulate p53 transcriptional activity³³ positively regulate p53 transcriptional activity
p53 is a master regulator of cellular stress responses; when p53 is activated, it can trigger cell-cycle arrest or apoptosis depending on context, mediating G1 cell-cycle arrest and apoptosis. ZNF346 is expressed in ovarian tissue (11.9 nTPM, Human Protein Atlas) and at notably higher levels in granulosa cells (21.1 nCPM), the somatic cells that nurse follicles and regulate their fate. Altered ZNF346 expression — potentially driven by the eQTL effects of the 5q35.2 haplotype — may modulate granulosa cell survival and follicular apoptosis thresholds. Whether rs244715 itself directly alters ZNF346 expression or function in the ovary remains under investigation.

Separately, a 2021 study found that rs244715 was associated with anti-Hsp27 antibody titers⁴⁴ anti-Hsp27 antibody titers
Heat shock protein 27 (Hsp27) is a stress-response chaperone; elevated anti-Hsp27 antibodies are a marker of immune activation and oxidative stress in premature menopause cases, suggesting a possible inflammatory or oxidative-stress component to this variant's effect on ovarian aging.

The Evidence

The 5q35.2 locus has been replicated in multiple large-scale studies. The He et al. 2009 discovery GWAS⁵⁵ He et al. 2009 discovery GWAS
n=17,438 women, European ancestry; four menopause loci identified at p<1×10⁻⁷ was confirmed by the Stolk et al. 2012 ReproGen meta-analysis⁶⁶ Stolk et al. 2012 ReproGen meta-analysis
n=38,968 discovery + 14,435 replication, 22 independent European-ancestry cohorts, which identified the 5q35.2 locus as one of 13 independent menopause-timing signals. The index variant rs365132 in UIMC1 had a beta of approximately 0.29 years (~15 weeks) per minor allele in the original discovery cohort.

The Breakthrough Generations Study⁷⁷ Breakthrough Generations Study
Murray et al. 2011, Hum Mol Genet, n=2,007 women including 694 early menopause cases; UK prospective cohort directly evaluated rs244715 and found the G allele yields an OR of 1.20 (95% CI 1.09–1.32, p=1.7×10⁻⁴) for early menopause (defined as menopause before age 46). Women homozygous for risk alleles across all four 2009 GWAS loci (including rs244715 GG) had approximately 4-fold higher odds of early menopause than women with three or fewer risk alleles. The per-allele effect on age at menopause in this study was 0.059 years, though this did not reach significance in the smaller quantitative trait analysis.

The Mashhad premature ovarian insufficiency cohort⁸⁸ Mashhad premature ovarian insufficiency cohort
Ziaee et al. 2021, 117 POI cases vs. 183 controls; Iranian women found allelic association of rs244715 G with POI (OR 1.71, 95% CI 1.17–2.50, p=0.005). The homozygote contrast (GG vs. AA) had an OR of 3.93 (95% CI 1.40–11.00, p=0.009) — a large effect consistent with an additive architecture — though none of these associations survived Bonferroni correction for the eight SNPs studied. The 5q35.2 locus was further extended in the Day et al. 2015 expanded GWAS⁹⁹ Day et al. 2015 expanded GWAS
n~70,000 European women; 54 independent signals in 44 genomic regions identified, confirming this as a durable, replicated signal.

Multi-ethnic replication is incomplete. The PAGE study¹⁰¹⁰ PAGE study
Carty et al. 2013, multi-ethnic US cohorts found rs365132 (the UIMC1 index SNP) significantly replicated in non-European populations, though the LD structure at the locus varies substantially across ancestries, meaning rs244715 may be a less reliable proxy in non-European groups.

Practical Implications

With an estimated per-allele shift of roughly 2–3 weeks in menopause timing, rs244715 has a modest individual effect. Its clinical utility lies in contributing to a polygenic burden score for ovarian aging — when combined with other replicated loci (MCM8 rs16991615, PRRC2A rs1046089, FNDC4 rs2303369), the cumulative genetic signal becomes more predictive of early reproductive aging than any single variant.

For women with the GG genotype who are considering when to start their family or whether to investigate fertility preservation, this variant is most informative when interpreted alongside AMH (anti-Müllerian hormone) levels — the most sensitive biomarker of remaining ovarian reserve — and antral follicle count on ultrasound.

The DNA repair context of this locus also raises a plausible lifestyle modulator: oxidative stress is a key driver of follicular DNA damage, and the 5q35.2 locus mechanism suggests that factors increasing cellular oxidative load (smoking, chronic inflammation) may interact with reduced UIMC1/ZNF346 pathway efficiency. However, there is currently no published evidence directly testing this gene-environment interaction.

Interactions

UIMC1 rs365132: The biological index SNP at this locus. rs244715 and rs365132 are in partial LD (r²=0.677 in Europeans), meaning they are highly correlated but not perfectly interchangeable. rs365132 (a synonymous UIMC1 coding variant) is the more functionally annotated variant and may be a better proxy for the biological effect at this locus. If a user has both, interpret the more significant association; they should not be treated as independent signals.

MCM8 rs16991615 (E341K): The strongest-effect DNA repair locus for menopause timing (~1 year per allele). Both MCM8 and the UIMC1/ZNF346 locus operate through overlapping DNA repair pathways (MCM8: replication fork restart; UIMC1: BRCA1-mediated DSB repair). A woman carrying risk alleles at both loci has two independent DNA-repair hits on reproductive lifespan. The combined signal may warrant earlier AMH baseline assessment.

A proposed compound action: Women who carry GG at rs244715 and carry the risk genotype at MCM8 rs16991615 (GG, associated with earlier menopause/lower AMH) represent an additive polygenic burden from two independent DNA-repair loci. The combined recommendation would be to obtain a baseline AMH panel before age 30, with repeat testing at 2-year intervals, and to discuss reproductive timeline planning with a reproductive endocrinologist if AMH is trending below age-expected norms.

PRRC2A rs1046089: A distinct menopause-timing locus on chromosome 6 operating through an immune/HLA pathway rather than DNA repair. rs244715 and rs1046089 are on different chromosomes and have no LD relationship — they are independent signals. Carrying risk alleles at both would represent additive contributions from two biologically distinct pathways (DNA repair and immune-mediated follicle depletion) to earlier ovarian aging.

Von Willebrand factor (VWF) is a multimeric glycoprotein essential for primary hemostasis. Under shear stress — in the turbulent flow of small vessels or at a wound site — ultra-large VWF multimers unfurl to capture platelets via their GPIb receptors, forming the platelet plug that stops bleeding before coagulation factors reinforce it. The size of the multimer matters: only the high-molecular-weight (HMW) forms¹¹ high-molecular-weight (HMW) forms
The largest VWF multimers carry the most platelet-binding A1 domains and collagen-binding A3 domains; their loss cannot be compensated by increased total VWF antigen are mechanically competent to bridge platelets to collagen under flow. The Y1146C variant in the D3 domain knocks out precisely those critical large forms, producing von Willebrand disease type 2A/IIE — and it does so in a single heterozygous copy.

The Mechanism

The VWF gene on chromosome 12p13.31 encodes a 2,813-amino-acid pre-pro-protein. After signal peptide cleavage and propeptide removal, mature VWF subunits dimerize and then multimerize²² dimerize and then multimerize
VWF dimerizes head-to-tail via C-terminal CK domain disulfide bonds in the endoplasmic reticulum, then multimerizes head-to-head via N-terminal disulfide bonds — forming chains of 20–40+ subunits stored in Weibel-Palade bodies through precisely orchestrated disulfide bonding in the D3 domain.

The Y1146C substitution introduces a rogue cysteine residue³³ introduces a rogue cysteine residue
Tyr1146 is normally a hydroxyl-bearing aromatic residue. Replacing it with cysteine adds a free thiol that forms aberrant disulfide bonds, disrupting local D3 domain folding into the D3 domain — the very region that mediates the initial head-to-head multimerization steps. In vitro expression studies confirm that Y1146C-mutant VWF shows severe reduction in or complete absence of HMW monomers⁴⁴ Y1146C-mutant VWF shows severe reduction in or complete absence of HMW monomers
Recombinant expression of Y1146C demonstrated intracellular retention of most mutant protein and failure to secrete HMW forms, with decreased secreted VWF antigen levels. The dominant-negative effect of one misfolded allele is sufficient to deplete large multimers from plasma.

The resulting multimer profile is the laboratory hallmark of type 2A VWD: normal or mildly reduced VWF antigen, but complete absence of the large and intermediate multimers on gel electrophoresis. VWF ristocetin cofactor activity (VWF:RCo) is disproportionately reduced relative to antigen — the ratio that distinguishes qualitative defects from simple quantitative deficiency.

The Evidence

Schneppenheim and colleagues⁵⁵ Schneppenheim and colleagues
Blood 2010, 115:4894–4901; 57 patients from 38 unrelated families with type 2A/IIE multimer pattern identified a cluster of 22 mutations in the VWF D3 domain responsible for a distinct type 2A subgroup (previously described in single families as type IIE). Y1146C was by far the most common, found in 12 of 38 probands (32%). Most mutations in this cluster affect cysteine residues — either creating new cysteines (like Y1146C) or destroying existing ones — consistent with the central role of disulfide bond architecture in D3 domain function. Pathogenicity was confirmed by expression studies and phenotypic characterization of recombinant mutant proteins.

Clinical presentation among Y1146C carriers ranged from mild to severe mucocutaneous bleeding, reflecting the heterogeneity typical of type 2A: epistaxis, easy bruising, prolonged bleeding after dental procedures, heavy menstrual bleeding, and postoperative hemorrhage. The variable expressivity likely reflects contributions from modifier genes, blood type O (which lowers VWF levels by ~25%), and acquired factors.

Therapeutic responsiveness to desmopressin (DDAVP) in type 2A VWD is mutation-dependent⁶⁶ desmopressin (DDAVP) in type 2A VWD is mutation-dependent
A 2022 study of 250 VWD patients showed only 31% of type 2 patients achieve complete DDAVP response; response is highly variant-specific and can be predicted by genotype. For D3-cluster mutations like Y1146C, even when VWF antigen rises after DDAVP infusion, the released VWF lacks HMW multimers and functional activity remains impaired — making VWF concentrate the preferred treatment modality for this variant.

Practical Actions

The 2021 ASH/ISTH/NHF/WFH guidelines⁷⁷ 2021 ASH/ISTH/NHF/WFH guidelines
Joint guidelines from four major hematology/hemostasis societies providing evidence-based management for all VWD subtypes recommend that type 2A patients requiring hemostasis support receive VWF concentrate rather than desmopressin as first-line therapy, particularly for surgical prophylaxis and major bleeding. Tranexamic acid (an antifibrinolytic) serves as an effective adjunct for mucosal bleeding and minor procedures. Women with heavy menstrual bleeding benefit from hormonal therapy (combined oral contraceptives or progestin-only) or tranexamic acid.

All carriers — including those with mild phenotypes — should have their bleeding history formally assessed and be evaluated by a hematologist experienced in bleeding disorders. A formal DDAVP trial with multimer analysis before and after infusion determines individual responsiveness and informs pre-procedural planning.

Interactions

Blood type O is a significant modifier: O-type individuals have approximately 25% lower VWF levels at baseline, which compounds with the multimer loss from Y1146C to produce more severe bleeding phenotypes. Patients with blood group O and Y1146C may present with more pronounced laboratory abnormalities and symptom burden than AB-type carriers.

Factor V Leiden (rs6025) and the prothrombin G20210A variant (rs1799963) can partially counterbalance a mild bleeding diathesis in Y1146C carriers — though this interaction is theoretical rather than clinically well-documented, and coexisting thrombophilia in a VWD patient complicates management substantially.